These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11144460)

  • 21. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):689-94. PubMed ID: 11294011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence of isoniazid in a two drug fixed dose combination and in a single drug dosage form.
    Agrawal S; Kaul CL; Panchagnula R
    Pharmazie; 2001 Aug; 56(8):636-9. PubMed ID: 11534341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimate of the global market for rifampicin-containing fixed-dose combination tablets.
    Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.
    Blomberg B; Spinaci S; Fourie B; Laing R
    Bull World Health Organ; 2001; 79(1):61-8. PubMed ID: 11217670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
    Ashokraj Y; Agrawal S; Varma MV; Singh I; Gunjan K; Kaur KJ; Bhade SR; Kaul CL; Caudron JM; Pinel J; Panchagnula R
    Int J Tuberc Lung Dis; 2004 Sep; 8(9):1081-8. PubMed ID: 15455592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement.
    Fourie PB; Spinaci S
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S368-70; discussion S381-7. PubMed ID: 10593720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of oral rifampicin in AIDS patients.
    Jaruratanasirikul S
    J Med Assoc Thai; 1998 Jan; 81(1):25-8. PubMed ID: 9470318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
    Catalani E
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S289-91; discussion S317-21. PubMed ID: 10593707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
    Agrawal S; Panchagnula R
    Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 33. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin.
    Panchagnula R; Agrawal S
    Int J Pharm; 2004 Mar; 271(1-2):1-4. PubMed ID: 15129967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization.
    Tuber Lung Dis; 1994 Jun; 75(3):180-1. PubMed ID: 7919308
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
    Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
    Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
    Singh S; Mariappan TT; Bhutani H
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):701-2. PubMed ID: 15971403
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of bioavailability of two brands of rifampicin.
    Bhatt AD; Revankar SN
    J Assoc Physicians India; 1999 Jul; 47(7):752. PubMed ID: 10778615
    [No Abstract]   [Full Text] [Related]  

  • 38. Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man.
    Chouchane N; Barre J; Toumi A; Tillement JP; Benakis A
    Eur J Drug Metab Pharmacokinet; 1995; 20(4):315-20. PubMed ID: 8983939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-dose combination formulations for tuberculosis treatment.
    Sbarbaro J; Blomberg B; Chaulet P
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S286-8. PubMed ID: 10593706
    [No Abstract]   [Full Text] [Related]  

  • 40. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms.
    Agrawal S; Panchagnula R
    Pharmazie; 2004 Oct; 59(10):775-81. PubMed ID: 15544056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.